Tags

Type your tag names separated by a space and hit enter

A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge.
Nat Commun. 2020 12 16; 11(1):6402.NC

Abstract

The COVID-19 pandemic caused by SARS-CoV-2 imposes an urgent need for rapid development of an efficient and cost-effective vaccine, suitable for mass immunization. Here, we show the development of a replication competent recombinant VSV-∆G-spike vaccine, in which the glycoprotein of VSV is replaced by the spike protein of SARS-CoV-2. In-vitro characterization of this vaccine indicates the expression and presentation of the spike protein on the viral membrane with antigenic similarity to SARS-CoV-2. A golden Syrian hamster in-vivo model for COVID-19 is implemented. We show that a single-dose vaccination results in a rapid and potent induction of SARS-CoV-2 neutralizing antibodies. Importantly, vaccination protects hamsters against SARS-CoV-2 challenge, as demonstrated by the abrogation of body weight loss, and alleviation of the extensive tissue damage and viral loads in lungs and nasal turbinates. Taken together, we suggest the recombinant VSV-∆G-spike as a safe, efficacious and protective vaccine against SARS-CoV-2.

Authors+Show Affiliations

Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel.Israel Institute for Biological Research, Ness Ziona, Israel. nirp@iibr.gov.il.Israel Institute for Biological Research, Ness Ziona, Israel. tomeri@iibr.gov.il.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

33328475

Citation

Yahalom-Ronen, Yfat, et al. "A Single Dose of Recombinant VSV-∆G-spike Vaccine Provides Protection Against SARS-CoV-2 Challenge." Nature Communications, vol. 11, no. 1, 2020, p. 6402.
Yahalom-Ronen Y, Tamir H, Melamed S, et al. A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge. Nat Commun. 2020;11(1):6402.
Yahalom-Ronen, Y., Tamir, H., Melamed, S., Politi, B., Shifman, O., Achdout, H., Vitner, E. B., Israeli, O., Milrot, E., Stein, D., Cohen-Gihon, I., Lazar, S., Gutman, H., Glinert, I., Cherry, L., Vagima, Y., Lazar, S., Weiss, S., Ben-Shmuel, A., ... Israely, T. (2020). A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge. Nature Communications, 11(1), 6402. https://doi.org/10.1038/s41467-020-20228-7
Yahalom-Ronen Y, et al. A Single Dose of Recombinant VSV-∆G-spike Vaccine Provides Protection Against SARS-CoV-2 Challenge. Nat Commun. 2020 12 16;11(1):6402. PubMed PMID: 33328475.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge. AU - Yahalom-Ronen,Yfat, AU - Tamir,Hadas, AU - Melamed,Sharon, AU - Politi,Boaz, AU - Shifman,Ohad, AU - Achdout,Hagit, AU - Vitner,Einat B, AU - Israeli,Ofir, AU - Milrot,Elad, AU - Stein,Dana, AU - Cohen-Gihon,Inbar, AU - Lazar,Shlomi, AU - Gutman,Hila, AU - Glinert,Itai, AU - Cherry,Lilach, AU - Vagima,Yaron, AU - Lazar,Shirley, AU - Weiss,Shay, AU - Ben-Shmuel,Amir, AU - Avraham,Roy, AU - Puni,Reut, AU - Lupu,Edith, AU - Bar-David,Elad, AU - Sittner,Assa, AU - Erez,Noam, AU - Zichel,Ran, AU - Mamroud,Emanuelle, AU - Mazor,Ohad, AU - Levy,Haim, AU - Laskar,Orly, AU - Yitzhaki,Shmuel, AU - Shapira,Shmuel C, AU - Zvi,Anat, AU - Beth-Din,Adi, AU - Paran,Nir, AU - Israely,Tomer, Y1 - 2020/12/16/ PY - 2020/06/18/received PY - 2020/11/17/accepted PY - 2020/12/17/entrez PY - 2020/12/18/pubmed PY - 2020/12/23/medline SP - 6402 EP - 6402 JF - Nature communications JO - Nat Commun VL - 11 IS - 1 N2 - The COVID-19 pandemic caused by SARS-CoV-2 imposes an urgent need for rapid development of an efficient and cost-effective vaccine, suitable for mass immunization. Here, we show the development of a replication competent recombinant VSV-∆G-spike vaccine, in which the glycoprotein of VSV is replaced by the spike protein of SARS-CoV-2. In-vitro characterization of this vaccine indicates the expression and presentation of the spike protein on the viral membrane with antigenic similarity to SARS-CoV-2. A golden Syrian hamster in-vivo model for COVID-19 is implemented. We show that a single-dose vaccination results in a rapid and potent induction of SARS-CoV-2 neutralizing antibodies. Importantly, vaccination protects hamsters against SARS-CoV-2 challenge, as demonstrated by the abrogation of body weight loss, and alleviation of the extensive tissue damage and viral loads in lungs and nasal turbinates. Taken together, we suggest the recombinant VSV-∆G-spike as a safe, efficacious and protective vaccine against SARS-CoV-2. SN - 2041-1723 UR - https://www.unboundmedicine.com/medline/citation/33328475/A_single_dose_of_recombinant_VSV_∆G_spike_vaccine_provides_protection_against_SARS_CoV_2_challenge_ L2 - https://doi.org/10.1038/s41467-020-20228-7 DB - PRIME DP - Unbound Medicine ER -